Accuray Incorporated (NASDAQ:ARAY) Shares Acquired by Jane Street Group LLC

Jane Street Group LLC lifted its position in shares of Accuray Incorporated (NASDAQ:ARAY) by 26.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 161,653 shares of the medical equipment provider’s stock after purchasing an additional 33,417 shares during the period. Jane Street Group LLC’s holdings in Accuray were worth $291,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in ARAY. Renaissance Technologies LLC increased its position in Accuray by 0.3% in the 2nd quarter. Renaissance Technologies LLC now owns 2,812,184 shares of the medical equipment provider’s stock valued at $5,118,000 after acquiring an additional 7,500 shares during the period. Foundry Partners LLC increased its position in Accuray by 51.3% in the 3rd quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock valued at $3,937,000 after acquiring an additional 741,900 shares during the period. State Street Corp increased its position in Accuray by 3.8% in the 3rd quarter. State Street Corp now owns 1,894,287 shares of the medical equipment provider’s stock valued at $3,410,000 after acquiring an additional 70,008 shares during the period. FMR LLC increased its position in Accuray by 27.2% in the 3rd quarter. FMR LLC now owns 582,591 shares of the medical equipment provider’s stock valued at $1,049,000 after acquiring an additional 124,459 shares during the period. Finally, Armistice Capital LLC acquired a new position in Accuray in the 2nd quarter valued at about $910,000. Institutional investors and hedge funds own 64.08% of the company’s stock.

Accuray Stock Performance

NASDAQ ARAY opened at $2.14 on Friday. The company has a current ratio of 1.63, a quick ratio of 0.87 and a debt-to-equity ratio of 3.59. The business’s 50 day moving average is $1.96 and its two-hundred day moving average is $1.90. Accuray Incorporated has a 12-month low of $1.40 and a 12-month high of $2.99. The stock has a market capitalization of $215.21 million, a price-to-earnings ratio of -12.59 and a beta of 1.47.

Accuray (NASDAQ:ARAY) last released its earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. The company had revenue of $101.55 million for the quarter, compared to analysts’ expectations of $98.10 million. During the same quarter in the previous year, the firm posted ($0.03) EPS. Research analysts expect that Accuray Incorporated will post 0.01 EPS for the current year.

Analyst Ratings Changes

Separately, StockNews.com cut Accuray from a “buy” rating to a “hold” rating in a research report on Friday, November 15th.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.